Physician profile
Mohamed Erritouni
NPI 1396924734
$33,802.91
in general payments reported to CMS, 2019-2025
15 companies · $4,405 in 2025
The $4,405 reported for 2025 was more than what 90% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $431 · 2021: $667 · 2022: $986 · 2023: $13K · 2024: $14K · 2025: $4,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $30K · Food and Beverage: $1,332 · Education: $90.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,950.00 |
| Food and Beverage | $1,332.49 |
| Education | $90.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $31,271.47 | 2019-2025 | Vibativ |
| Merck Sharp & Dohme LLC | $747.76 | 2019-2025 | Zerbaxa, Dificid, Zinplava |
| Shionogi INC | $465.59 | 2020-2025 | Fetroja |
| Melinta Therapeutics, LLC | $334.92 | 2019-2025 | Kimyrsa, Vabomere, Orbactiv |
| Abbvie INC. | $174.44 | 2021-2022 | |
| Gilead Sciences, INC. | $154.99 | 2020-2022 | |
| Angiodynamics, INC. | $123.23 | 2023 | Auryon Laser System 100-120 Vac |
| La Jolla Pharmaceutical Company | $121.14 | 2022-2023 | Xerava |
| Paratek Pharmaceuticals, INC. | $114.86 | 2020-2022 | |
| Insmed, INC. | $111.05 | 2021-2025 | Arikayce, Brinsupri |
| Tetraphase Pharmaceuticals, INC. | $57.98 | 2019-2020 | |
| Viiv Healthcare Company | $48.80 | 2022-2024 | Dovato |
| Allergan, INC. | $35.16 | 2020 | |
| Nabriva Therapeutics, Plc | $23.45 | 2021 | |
| Ferring Pharmaceuticals INC. | $18.07 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Erritouni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.